WO1995000155A1 - Method for the improvement of wound healing and compositions therefor - Google Patents
Method for the improvement of wound healing and compositions therefor Download PDFInfo
- Publication number
- WO1995000155A1 WO1995000155A1 PCT/FI1994/000252 FI9400252W WO9500155A1 WO 1995000155 A1 WO1995000155 A1 WO 1995000155A1 FI 9400252 W FI9400252 W FI 9400252W WO 9500155 A1 WO9500155 A1 WO 9500155A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- colostrum
- fraction
- colostrum fraction
- ultrafiltration
- healing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
- A61K8/986—Milk; Derivatives thereof, e.g. butter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Definitions
- This invention relates to a method for the improvement of the healing of wounds in mammals including humans by using a colostrum fraction.
- the invention relates further to pharmaceutical or cosmetic compositions of said colostrum fraction.
- the term "improving the healing of wounds” in the present text refers to the taking of steps by means of which wounds showing no tendency to heal are induced to start the healing process, and wounds that have started to heal are induced to heal more quickly; or to the taking of steps which are conductive to a cosmetic improvement of the functional result during the healing or after the completion thereof. Improvement of wound healing is particularly important when natural healing is slow or is rendered difficult by a number of negative factors like e.g. infection of the wound, impeded blood flow, medical treatments with cell poisons or with steroids of various kinds, or in cases where patients suffer from chronical disorders with concomitant impairment of normal wound healing e.g.
- EGF epidermal growth factor
- PDGF platelet derived growth factor
- the main cell types of skin consists of epidermal keratinocytes and dermal fibroblasts.
- epidermal keratinocytes For wound healing it would be beneficial if the growth and/or migration of epidermal keratinocytes could be promoted. Also for the general skin care keratinocyte growth stimulation can help to maintain the healthy look of skin.
- the object of the invention is to provide a method for the improvement of the healing of wounds in mammals including humans.
- the main object is to obtain an enhanced growth of epithelial layer while inhibiting the overgrowth of connective tissue.
- Another object of the invention is to provide pharmaceutical or cosmetic compositions, particularly compositions to be used in said method for improving the healing of wounds in mammals including humans.
- FIGS 1A and IB demonstrate transdermal preparations.
- Figure 2 demonstrates the stimulation of keratinocyte DNA synthesis by different concentrations of colostrum fraction.
- Figure 3 discloses proliferation of HaCat cells in vitro in 10 % FCS (triangles), 1 % adult bovine serum (circles) and 1 % adult bovine serum + 5 % CF (squares) .
- the inventors have found that a colostrum fraction containing the growth factors of colostrum stimulate the growth of the keratin layer very strongly while it simultaneously inhibits the growth of the granulation tissue.
- Bovine colostrum fractions rich in growth factors are known as excellent additives to cell culture media to promote the growth of cells, particularly hybridoma cells.
- the invention thus concern a method for improving the healing of wounds in mammals including humans which comprises locally administering to said mammal a safe and effective amount of a colostrum fraction, said colostrum fraction having been prepared by subjecting colostrum, from which part of the fat and cellular debris have been removed by conventional methods such as centrifugation, to ultrafiltration by using a membrane having a cut off of 100,000 Da and recovering the filtrate.
- the invention further concerns a pharmaceutical or cosmetic composition, particularly a composition for improving the healing of wounds in mammals including humans comprising a colostrum fraction, said colostrum fraction having been prepared by subjecting colostrum, from which part of the fat and cellular debris have been removed by conventional methods, to ultrafiltration by using a membrane having a cut off of 100,000 Da and recovering the filtrate, and a compatible non-toxic carrier therefor.
- a pharmaceutical or cosmetic composition particularly a composition for improving the healing of wounds in mammals including humans comprising a colostrum fraction, said colostrum fraction having been prepared by subjecting colostrum, from which part of the fat and cellular debris have been removed by conventional methods, to ultrafiltration by using a membrane having a cut off of 100,000 Da and recovering the filtrate, and a compatible non-toxic carrier therefor.
- casein has been removed from the colostrum by precipitation previous to its ultrafiltration.
- the removal of casein results in lower endotoxin and immunoglobulin contents in the ultrafiltrated colostrum fraction.
- the colostrum fraction is for practical reasons preferably obtained from bovine colostrum. Colostrum from other sources is, however, also believed to be useful for the preparation of the colostrum fraction to be used in this invention.
- the topical or transdermal administration of the colostrum fraction can be accomplished mainly in three different ways: (i) by mixing (or adsorbing) an effective amount of the colostrum fraction with suitable non-toxic carriers and optionally penetration enhancers to form ointments, emulsions, solutions, suspensions, lotions, creams, gels, powders, aerosols, bandage patches or the like, where preferably a fixed amount of said formulation is to be applied onto the wound, or (ii) by incorporating the colostrum fraction into a transdermal delivery system according to known technology, or (iii) by incorporating the bioactive substances from the colostrum fraction into liposomes which can either be used as such or can be incorporated in the formulations of the previous alternatives (i) or (ii).
- the role of the transdermal administration is mainly to transport the colostrum fraction through the epidermal layer and not necessarily to achieve a systemic effect.
- excipients include those well known in the art of pharmacy and cosmetology for the preparation of topical formulations such as aqueous buffered saline solutions, non-volatile fatty alcohols, acids, esters, e.g. cetostearyl alcohol and cetyl alcohol; volatile alcoholic compounds, e.g. ethanol and isopropanol; glycols and glycol ethers.
- peptic ulcers The healing of wounds in the stomach or the intestine, i.e. peptic ulcers can also be improved by use of the method according to the invention.
- the colostrum fraction can be used as such combined with flavouring agents and preservatives.
- the colostrum fraction can be absorbed into particles or into a matrix, which optionally could be coated with a material having slow release or enteric properties.
- the matrix or particles can further be pressed into tablets or put into capsules.
- Whey was prepared from defatted colostrum by rempval of casein using acid precipitation, (see, for example, R. Pakkanen et al., Appl. Microbiol Biotechnol (1992) 37; p. 452.).
- An ultrafiltrate was obtained from cleared whey by filtration throuhg membranes with a nomonal molecular weight cut-off of 100,000 Da.
- the colostrum ultrafiltrate (colostrum fraction) so obtained contained l.lg g/1 protein, 0.24 g/1 immunoglobulin G (IgG) and less than 0.24 EU (endotoxin unit)/ml endotoxins.
- the colostrum fraction can be incorporated into a transdermal drug delivery device. Such devices are illustrated in Fig. 1A and IB, where reference number 1 represents an backing layer, 2 is an adhesive layer, which keeps the patch attached to the skin and 3 is a porous polymer.
- reference number 1 represents an backing layer
- 2 is an adhesive layer, which keeps the patch attached to the skin
- 3 is a porous polymer.
- the colostrum fraction has been absorbed into the porous polymer 3, either alone or in combination with a vehicle and/or a penetration enhancer.
- the reservoir 4 contains the colostrum fraction solution.
- liposomes of the above mixture are either the use of the French press or the membrane extrusion method.
- the required dose of the colostrum fraction will vary especially with the particular kind of wound to be treated, the severity of its condition and the dosage form. We believe that a suitable dose could range from some millilitres to one litre or more of colostrum fraction per day and adult person.
- the preferred dose for topical or transdermal preparations would be about 0.5 - 1 ml/day and cm 2 of wound area.
- the preferable oral dosage is believed to be about 50 to 1000 ml per day and adult person.
- the therapeutic effect of the colostrum fraction is demonstrated by the following non-limiting examples.
- the colostrum fraction used in the experiments had an endotoxin content of 1.0 EU/ml, a total protein content of 2.0 mg/ml and an immunoglobulin content of 0.25 mg/ml.
- the fraction can was obtained by subjecting the defatted colostrum to casein precipitation before the ultrafiltration.
- CF colostrum fraction
- HaCat cells were divided into petri dishes and grown until semi-confluent. After that cells were maintained 24 h in serum free medium following the addition of different concentrations of CF and FCS. Cells were incubated with these solutions for next 24 h after which I-deoxiuridine was added for an additional 2 hours. Finally cells were washed with cold PBS, fixed and extracted into 0.2 M NaOH. Radioactivity remaining in the cell extracts was measured with a gamma counter.
- Figure 2 demonstrates the stimulation of keratinocyte DNA synthesis by CF.
- Human keratinocytes were plated on culture dishes and grown to semiconfluency in the presence of 10 % FCS. After 24-h starvation in plain culture medium, media containing different concentrations of CF or 10 % FCS were added for following 24 hours. At the end of the incubation DNA synthesis rates were measured by adding 125 ⁇ - deoxyuridine into cultures for additional two hours and measuring the rates of IdU incorporations. Mean ⁇ S.D. of four samples are presented.
- CF contains growth factors which stimulate proliferation of HaCat cells in vitro. Moreover, the results suggest that these factors are either not present in normal adult bovine serum or their concentration is significantly higher in CF.
- Viscose cellulose sponge (Sateri Oy, Valkeakoski, Finland) was used as an inductive matrix for repair tissue. The material was cut into cylindrical pieces, 40 mm long and 10 mm in diameter, and a tunnel of 3 mm in diameter was made through the center of the sponge. Silicone rubber discs, 10 mm in diameter and 2 mm thick, were stiched onto both ends of the sponge to create a stable dead space. The cylinders were decontaminated by boiling for 30 min in physiological saline and the implantations were performed with strictly aseptic techniques.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Birds (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE69431300T DE69431300T2 (en) | 1993-06-23 | 1994-06-13 | A PHARMACEUTICAL OR COSMETIC PREPARATION THAT CONTAINS A COLOSTRUM FACTION AND THEIR MEDICAL USE |
AU68478/94A AU6847894A (en) | 1993-06-23 | 1994-06-13 | Method for the improvement of wound healing and compositions therefor |
EP94917019A EP0711171B1 (en) | 1993-06-23 | 1994-06-13 | A pharmaceutical or cosmetic composition comprising a colostrum fraction and its medical use |
FI956064A FI956064A (en) | 1993-06-23 | 1995-12-15 | Method for promoting wound healing and compositions suitable therefor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8021893A | 1993-06-23 | 1993-06-23 | |
US08/080,218 | 1993-06-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995000155A1 true WO1995000155A1 (en) | 1995-01-05 |
Family
ID=22156003
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FI1994/000252 WO1995000155A1 (en) | 1993-06-23 | 1994-06-13 | Method for the improvement of wound healing and compositions therefor |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0711171B1 (en) |
AU (1) | AU6847894A (en) |
DE (1) | DE69431300T2 (en) |
EE (1) | EE9400174A (en) |
WO (1) | WO1995000155A1 (en) |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996034614A1 (en) * | 1995-05-02 | 1996-11-07 | Gropep Pty. Ltd. | Method of preventing or treating alimentary tract damage due to chemotherapy or radiation |
WO1997026898A1 (en) * | 1996-01-24 | 1997-07-31 | Sylvie Limited | Gastro-resistant pharmaceutical formulations containing colostrum and the use of colostrum for the treatment of insomnia |
DE19619990A1 (en) * | 1996-05-17 | 1997-11-20 | Charlotte Adler | Process for the production of colostral milk products and their use |
WO1998011904A1 (en) * | 1996-09-20 | 1998-03-26 | Scientific Hospital Supplies International Limited | Prevention of gastrointestinal damage |
WO1998011910A1 (en) * | 1996-09-20 | 1998-03-26 | Scientific Hospital Supplies International Limited | Prevention of gastrointestinal damage |
WO1998053836A1 (en) * | 1997-05-27 | 1998-12-03 | Anderson Michael R | Improved gelled oxygen products |
ES2139525A1 (en) * | 1997-11-17 | 2000-02-01 | Sanchez Pedro Cuevas | Use of whey-derived products as cytoprotectors and cicatrizants. |
WO2001003515A1 (en) * | 1999-07-07 | 2001-01-18 | New Zealand Co-Operative Dairy Company Limited | Method of obtaining protein isolates and concentrates from colostrum |
WO2001015750A1 (en) * | 1999-08-27 | 2001-03-08 | Department Of National Defence | Hydrogel wound dressing containing liposome-encapsulated therapeutic agent |
US6903068B1 (en) | 1999-08-17 | 2005-06-07 | Board Of Regents, The University Of Texas System | Use of colostrinin, constituent peptides thereof, and analogs thereof for inducing cytokines |
US6939847B2 (en) * | 1999-08-17 | 2005-09-06 | Board Of Regents, The University Of Texas System | Use of colostrinin, constituent peptides thereof, and analogs thereof, as oxidative stress regulators |
WO2006029518A1 (en) * | 2004-09-14 | 2006-03-23 | Nexcell Biosciences Inc. | Isolation of growth and differentiating factors from colostrum |
WO2006029494A1 (en) * | 2004-09-14 | 2006-03-23 | Nexcell Biosciences Inc. | Extraction of growth and differentiating factors from colostrum |
US7119064B2 (en) | 1999-08-17 | 2006-10-10 | Board Of Regents, The University Of Texas System | Use of colostrinin, constituent peptides thereof, and analogs thereof as modulators of intracellular signaling molecules |
WO2007000651A1 (en) * | 2005-06-29 | 2007-01-04 | Bionest Ltd. | Pharmaceutical and cosmetic compositions containing colostrum, tocopherols, zinc oxide and hyaluronic acid |
EP1814591A1 (en) * | 2004-11-22 | 2007-08-08 | Anadis Ltd. | Bioactive compositions |
ITMI20112446A1 (en) * | 2011-12-30 | 2013-07-01 | Bionest Ltd | COMPOSITION FOR THE THERAPY OF INJURIES OF ORAL MUCOSA |
ITMI20112445A1 (en) * | 2011-12-30 | 2013-07-01 | Bionest Ltd | USE OF CYTOCHINES, GROWTH FACTORS, ANTIBACTERIAL FACTORS AND ANTIBODIES, FOR THE TOPIC THERAPY OF ULCERS, PLEASURES AND SKIN BURNS |
WO2013098331A1 (en) | 2011-12-30 | 2013-07-04 | Bionest Ltd. | Combination of growth factors, cytokines, antibacterial/antiviral factors, stem cell stimulating factors, complement proteins c3a/c4a, and chemotactic factors |
WO2013098333A1 (en) | 2011-12-30 | 2013-07-04 | Bionest Ltd. | Combination of growth factors, cytokines, antibacterial/antiviral factors, stem cell stimulating factors, complement proteins c3a/c4a, immunoglobulins and chemotactic factors |
IT202000020971A1 (en) * | 2020-09-03 | 2022-03-03 | Solime S R L | PROCEDURE FOR THE PREPARATION OF CONCENTRATED COLOSTRUM |
IT202000024385A1 (en) * | 2020-10-15 | 2022-04-15 | Biomedical Res Srl | COMPOSITION BASED ON AUTOLOGOUS PLATELET CONCENTRATES AND A MIXTURE OF BIOLOGICAL FACTORS ISOLATED FROM COLOSTRUM FOR USE IN THE TREATMENT OF CONDITIONS REQUIRING TISSUE REPAIR AND REGENERATION |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2460135A1 (en) * | 1979-07-02 | 1981-01-23 | Liotet Serge | COMPOSITION FOR EXTERNAL USE BASED ON COLOSTRUM |
FR2627386A1 (en) * | 1988-02-22 | 1989-08-25 | Serge Liotet | Compsns. for topical application to eyes - contg. colostrum lactoserum and vitamin=a |
EP0334776A2 (en) * | 1988-03-25 | 1989-09-27 | Gattefosse S.A. | Cosmetical or pharmaceutical composition for cutaneous application, and process for the manufacture of such a composition |
FI893404A (en) * | 1989-07-13 | 1991-01-14 | Valio Meijerien | ANVAENDNING AV MJOELKFRAKTIONER FOER BEHANDLING OCH PROFYLAX AV ULCERATION OCH INFLAMMATORISKA TILLSTAOND I MATSMAELTNINGSKANALEN. |
-
1994
- 1994-06-13 AU AU68478/94A patent/AU6847894A/en not_active Abandoned
- 1994-06-13 DE DE69431300T patent/DE69431300T2/en not_active Expired - Fee Related
- 1994-06-13 WO PCT/FI1994/000252 patent/WO1995000155A1/en active IP Right Grant
- 1994-06-13 EP EP94917019A patent/EP0711171B1/en not_active Expired - Lifetime
- 1994-11-23 EE EE9400174A patent/EE9400174A/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2460135A1 (en) * | 1979-07-02 | 1981-01-23 | Liotet Serge | COMPOSITION FOR EXTERNAL USE BASED ON COLOSTRUM |
US4342747A (en) * | 1979-07-02 | 1982-08-03 | Serge Liotet | Colostrum-based composition for external use |
FR2627386A1 (en) * | 1988-02-22 | 1989-08-25 | Serge Liotet | Compsns. for topical application to eyes - contg. colostrum lactoserum and vitamin=a |
EP0334776A2 (en) * | 1988-03-25 | 1989-09-27 | Gattefosse S.A. | Cosmetical or pharmaceutical composition for cutaneous application, and process for the manufacture of such a composition |
FI893404A (en) * | 1989-07-13 | 1991-01-14 | Valio Meijerien | ANVAENDNING AV MJOELKFRAKTIONER FOER BEHANDLING OCH PROFYLAX AV ULCERATION OCH INFLAMMATORISKA TILLSTAOND I MATSMAELTNINGSKANALEN. |
Non-Patent Citations (1)
Title |
---|
DERWENT ABSTRACT, No. 92-248203/30, week 9230; & SU,A,1685253 (KOZLOV V K), 15 October 1991. * |
Cited By (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996034614A1 (en) * | 1995-05-02 | 1996-11-07 | Gropep Pty. Ltd. | Method of preventing or treating alimentary tract damage due to chemotherapy or radiation |
US6183784B1 (en) | 1995-05-02 | 2001-02-06 | Gropep Limited | Method of ameliorating alimentary tract damage due to chemotherapy or radiation |
WO1997026898A1 (en) * | 1996-01-24 | 1997-07-31 | Sylvie Limited | Gastro-resistant pharmaceutical formulations containing colostrum and the use of colostrum for the treatment of insomnia |
DE19619990A1 (en) * | 1996-05-17 | 1997-11-20 | Charlotte Adler | Process for the production of colostral milk products and their use |
WO1997043905A1 (en) * | 1996-05-17 | 1997-11-27 | Charlotte Adler | Process for production of colostral milk products and use thereof |
WO1998011904A1 (en) * | 1996-09-20 | 1998-03-26 | Scientific Hospital Supplies International Limited | Prevention of gastrointestinal damage |
WO1998011910A1 (en) * | 1996-09-20 | 1998-03-26 | Scientific Hospital Supplies International Limited | Prevention of gastrointestinal damage |
WO1998053836A1 (en) * | 1997-05-27 | 1998-12-03 | Anderson Michael R | Improved gelled oxygen products |
ES2139525A1 (en) * | 1997-11-17 | 2000-02-01 | Sanchez Pedro Cuevas | Use of whey-derived products as cytoprotectors and cicatrizants. |
WO2001003515A1 (en) * | 1999-07-07 | 2001-01-18 | New Zealand Co-Operative Dairy Company Limited | Method of obtaining protein isolates and concentrates from colostrum |
US7119064B2 (en) | 1999-08-17 | 2006-10-10 | Board Of Regents, The University Of Texas System | Use of colostrinin, constituent peptides thereof, and analogs thereof as modulators of intracellular signaling molecules |
US6903068B1 (en) | 1999-08-17 | 2005-06-07 | Board Of Regents, The University Of Texas System | Use of colostrinin, constituent peptides thereof, and analogs thereof for inducing cytokines |
US6939847B2 (en) * | 1999-08-17 | 2005-09-06 | Board Of Regents, The University Of Texas System | Use of colostrinin, constituent peptides thereof, and analogs thereof, as oxidative stress regulators |
WO2001015750A1 (en) * | 1999-08-27 | 2001-03-08 | Department Of National Defence | Hydrogel wound dressing containing liposome-encapsulated therapeutic agent |
WO2006029518A1 (en) * | 2004-09-14 | 2006-03-23 | Nexcell Biosciences Inc. | Isolation of growth and differentiating factors from colostrum |
WO2006029494A1 (en) * | 2004-09-14 | 2006-03-23 | Nexcell Biosciences Inc. | Extraction of growth and differentiating factors from colostrum |
US8252341B2 (en) | 2004-09-14 | 2012-08-28 | Paul Brazeau | Isolation of growth and differentiating factors from colostrum |
EP1814591A1 (en) * | 2004-11-22 | 2007-08-08 | Anadis Ltd. | Bioactive compositions |
EP1814591A4 (en) * | 2004-11-22 | 2009-04-22 | Anadis Ltd | Bioactive compositions |
AU2005306579B2 (en) * | 2004-11-22 | 2012-01-19 | Immuron Limited | Bioactive compositions |
EP2417986A1 (en) * | 2004-11-22 | 2012-02-15 | Anadis Ltd. | Bioactive compositions |
WO2007000651A1 (en) * | 2005-06-29 | 2007-01-04 | Bionest Ltd. | Pharmaceutical and cosmetic compositions containing colostrum, tocopherols, zinc oxide and hyaluronic acid |
ITMI20112446A1 (en) * | 2011-12-30 | 2013-07-01 | Bionest Ltd | COMPOSITION FOR THE THERAPY OF INJURIES OF ORAL MUCOSA |
ITMI20112445A1 (en) * | 2011-12-30 | 2013-07-01 | Bionest Ltd | USE OF CYTOCHINES, GROWTH FACTORS, ANTIBACTERIAL FACTORS AND ANTIBODIES, FOR THE TOPIC THERAPY OF ULCERS, PLEASURES AND SKIN BURNS |
WO2013098331A1 (en) | 2011-12-30 | 2013-07-04 | Bionest Ltd. | Combination of growth factors, cytokines, antibacterial/antiviral factors, stem cell stimulating factors, complement proteins c3a/c4a, and chemotactic factors |
WO2013098333A1 (en) | 2011-12-30 | 2013-07-04 | Bionest Ltd. | Combination of growth factors, cytokines, antibacterial/antiviral factors, stem cell stimulating factors, complement proteins c3a/c4a, immunoglobulins and chemotactic factors |
US9492512B2 (en) | 2011-12-30 | 2016-11-15 | Innomed S.A. | Combination of growth factors, cytokines, antibacterial/antiviral factors, stem cell stimulating factors, complement proteins C3A/C4A, and chemotactic factors |
US9555084B2 (en) | 2011-12-30 | 2017-01-31 | Innomed S.A. | Combination of growth factors, cytokines, antibacterial/antiviral factors, stem cell stimulating factors, complement proteins C3a/C4a, immunoglobulins and chemotactic factors |
EP3173087A1 (en) | 2011-12-30 | 2017-05-31 | Innomed S.A. | Combination of growth factors, cytokines, antibacterial/antiviral factors, stem cell stimulating factors, complement proteins c3a/c4a, and chemotactic factors |
RU2642650C2 (en) * | 2011-12-30 | 2018-01-25 | Инномед С.А. | Combination of growth factors, cytokines, antibacterial/antiviral factors, stem cells factors, c3a/s4a complement proteins, immunoglobulins and chemotactic factors |
US10098927B2 (en) | 2011-12-30 | 2018-10-16 | Innomed S.A. | Combination of growth factors, cytokines, antibacterial/antiviral factors, stem cell stimulating factors, complement proteins C3A/C4A, immunoglobulins and chemotactic factors |
IT202000020971A1 (en) * | 2020-09-03 | 2022-03-03 | Solime S R L | PROCEDURE FOR THE PREPARATION OF CONCENTRATED COLOSTRUM |
WO2022049531A1 (en) * | 2020-09-03 | 2022-03-10 | Solime' S.R.L. | Process for the preparation of colostrum concentrate |
IT202000024385A1 (en) * | 2020-10-15 | 2022-04-15 | Biomedical Res Srl | COMPOSITION BASED ON AUTOLOGOUS PLATELET CONCENTRATES AND A MIXTURE OF BIOLOGICAL FACTORS ISOLATED FROM COLOSTRUM FOR USE IN THE TREATMENT OF CONDITIONS REQUIRING TISSUE REPAIR AND REGENERATION |
WO2022079684A1 (en) * | 2020-10-15 | 2022-04-21 | Biomedical Research S.R.L. | Composition based on autologous platelet concentrates and a colostrum isolate mixture of biological factors for use in the treatment of conditions requiring tissue repair and regeneration |
Also Published As
Publication number | Publication date |
---|---|
EP0711171A1 (en) | 1996-05-15 |
AU6847894A (en) | 1995-01-17 |
EP0711171B1 (en) | 2002-09-04 |
DE69431300T2 (en) | 2003-07-31 |
DE69431300D1 (en) | 2002-10-10 |
EE9400174A (en) | 1996-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0711171B1 (en) | A pharmaceutical or cosmetic composition comprising a colostrum fraction and its medical use | |
US6541447B1 (en) | Wound healing composition and method for use thereof | |
US20120009233A1 (en) | Skin Care Compositions and Treatments | |
JPH0661262B2 (en) | Method of stimulating cell proliferation | |
WO1986002271A1 (en) | Promotion of wound healing with human epidermal growth factor prepared from recombinant dna | |
KR20040111355A (en) | Compositions comprising undifferentiated fetal cells for the treatment of skin disorders | |
KR102682677B1 (en) | Manufacturing method and usage of conditioned media which contains highly effective exosomes secreted by umbilical cord blood stem cells at high content | |
US6447808B2 (en) | Growth-promoting agent | |
US7011965B2 (en) | Compositions and methods for stimulating wound healing and fibroblast proliferation | |
WO2018150440A1 (en) | Stem cell conditioned media for clinical and cosmetic applications | |
WO2015122592A1 (en) | Composition for promoting wound healing | |
JPH09227565A (en) | Wound healing agent | |
JP4726300B2 (en) | Matrix protein composition for transplantation | |
EP0862438B1 (en) | sphingosylphosphorylcholine as a wound-healing agent | |
Schlemm et al. | Medicinal yeast extracts | |
US7033610B2 (en) | Growth-promoting agent | |
JPH0320206A (en) | Skin cosmetic | |
JPH03502922A (en) | Local wound treatment formulation containing interleukin-1 protein | |
US20240016893A1 (en) | Compositions and methods for treating wounds | |
WO2021039833A1 (en) | Method for producing cultured tissue, and preparation for external application | |
US11744856B1 (en) | Compositions and methods to improve skin quality and appearance, cure skin and tissue damage, and use in therapy | |
KR101706737B1 (en) | Wound-healing composition for external use and cosmetic composition containing rice cell-derived recombinant human granulocyte macrophage-colony stimulating factor | |
JPH0424329B2 (en) | ||
TW201726108A (en) | Use of polypeptide composition for preparation of anti-inflammatory medical product or cosmetic containing an effective dose of polypeptide composition and a pharmaceutically acceptable carrier applied to receptor | |
AU2012258457A1 (en) | Skin care compositions and treatments |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AT AU BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KE KG KP KR KZ LK LU LV MD NL NO NZ PL PT RO RU SE SI SK TJ TT UA US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 1995 564201 Country of ref document: US Date of ref document: 19951213 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1994917019 Country of ref document: EP Ref document number: 956064 Country of ref document: FI |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1994917019 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWG | Wipo information: grant in national office |
Ref document number: 1994917019 Country of ref document: EP |